{"id":1167,"date":"2017-01-31T21:35:01","date_gmt":"2017-01-31T20:35:01","guid":{"rendered":"http:\/\/www.newslab.sk\/2017\/01\/31\/europsky-kongres-klinickych-mikrobiologov-a-infektologov-v-amsterdame-prezentacia-nasich-vysledkov\/"},"modified":"2017-08-27T13:36:48","modified_gmt":"2017-08-27T11:36:48","slug":"european-congress-of-clinical-microbiologists-and-infectious-diseases-in-amsterdam-presentation-of-our-findings","status":"publish","type":"post","link":"https:\/\/www.newslab.sk\/en\/european-congress-of-clinical-microbiologists-and-infectious-diseases-in-amsterdam-presentation-of-our-findings\/","title":{"rendered":"European Congress of Clinical Microbiologists and Infectious Diseases in Amsterdam \u2013 presentation of our findings"},"content":{"rendered":"

V r\u00e1mci predn\u00e1\u0161kov\u00fdch blokov boli vzdel\u00e1vacie workshopy zameran\u00e9 na konkr\u00e9tnu oblas\u0165 alebo aktu\u00e1lnu problematiku, stretnutia s expertmi a r\u00f4zne symp\u00f3zi\u00e1. Bli\u017e\u0161ie inform\u00e1cie o podujat\u00ed n\u00e1jdete na webovej str\u00e1nke http:\/\/www.eccmid.org\/.<\/a><\/span><\/p>\n

Po predch\u00e1dzaj\u00facej akt\u00edvnej \u00fa\u010dasti pred dvomi rokmi na 24. ECCMID v Barcelone, \u00a0kde sa n\u00e1m podarilo prv\u00fdkr\u00e1t odprezentova\u0165 \u00a0poster s predbe\u017en\u00fdmi \u00a0v\u00fdsledkami lie\u010dby chronick\u00fdch \u00a0a recidivuj\u00facich kolpit\u00edd autovakc\u00ednami, sa n\u00e1m tentokr\u00e1t podarilo prebojova\u0165 medzi elektronick\u00e9 postery s \u00fastnou prezent\u00e1ciou. N\u00e1\u0161 poster s n\u00e1zvom \u201eTreatment of chronic and recurrent vulvovaginitis with autogenous microbial vaccines \u2013 a two year follow-up study\u201c po pos\u00faden\u00ed tromi nez\u00e1visl\u00fdmi recenzentmi zaradili do elektronickej posterovej sekcie s n\u00e1zvom \u201eVaccine research news between microbiota, seroprotection and attitudes\u201c pod \u010d\u00edslom EP0250. Sekciu moderovala Hanna M. Nohynek, expertka na vakcin\u00e1ciu z Hels\u00ednk. Poster som prezentovala v anglickom jazyku s 5 \u2013 6-min\u00fatov\u00fdm stru\u010dn\u00fdm prejavom, z\u00e1ujemcovia \u00a0kl\u00e1dli 1 \u2013 2 ot\u00e1zky.<\/p>\n

 <\/p>\n

Na\u0161a pr\u00e1ca pozost\u00e1vala z hodnotenia \u00faspe\u0161nosti lie\u010dby s\u00faboru 61 pacientok lie\u010den\u00fdch autovakc\u00ednami na chronick\u00e9 a recidivuj\u00face kolpit\u00eddy po\u010das rokov 2011 a\u017e 2013 a z hodnotenia ich zdravotn\u00e9ho stavu po\u010das dvoch rokov po ukon\u010den\u00ed lie\u010dby autovakc\u00ednami. U ka\u017edej pacientky sme zaznamen\u00e1vali inform\u00e1cie o zdravotnom stave a mikrobiologick\u00fdch kultiva\u010dn\u00fdch n\u00e1lezoch a hodnotili sme po\u010det recid\u00edv, ktor\u00e9 mali po\u010das 10-mesa\u010dnej lie\u010dby a v obdob\u00ed n\u00e1sledn\u00e9ho dvojro\u010dn\u00e9ho sledovania. \u0160t\u00fadiu sme ukon\u010dili v okt\u00f3bri 2015. Do skupiny \u00faspe\u0161ne lie\u010den\u00fdch pacientok sme zaradili pacientky, ktor\u00e9 nemali recid\u00edvu alebo mali len jednu recid\u00edvu po\u010das 10 mesiacov lie\u010dby autovakc\u00ednami (skupina S). Pacientky, ktor\u00e9 mali 2 recid\u00edvy po\u010das lie\u010dby, sme zaradili do skupiny \u010diasto\u010dne \u00a0\u00faspe\u0161ne \u00a0lie\u010den\u00fdch \u00a0(skupina P). Pacientky, ktor\u00e9 mali 3 a viac recid\u00edv, sme zaradili do skupiny ne\u00faspe\u0161ne \u00a0lie\u010den\u00fdch \u00a0(skupina F). Na konci 10-mesa\u010dnej lie\u010dby sme mali 41 (67,21 %) \u00faspe\u0161ne lie\u010den\u00fdch pacientok (skupina S), 12 (19,67 %) \u010diasto\u010dne \u00a0\u00faspe\u0161ne lie\u010den\u00fdch \u00a0(skupina P) a 8 (13,12 %) ne\u00faspe\u0161ne \u00a0lie\u010den\u00fdch \u00a0pacientok \u00a0(skupina F). N\u00e1sledne \u00a0po ukon\u010den\u00ed lie\u010dby v prvom aj v druhom roku sledovania sme hodnotili po\u010det recid\u00edv v jednotliv\u00fdch skupin\u00e1ch pacientok. Uk\u00e1zalo sa, \u017ee u 70 \u2013 78 % pacientok skupiny S pretrv\u00e1val v\u00fdrazne zlep\u0161en\u00fd zdravotn\u00fd stav po\u010das 2 rokov po skon\u010den\u00ed lie\u010dby. V\u00e4\u010d\u0161ina p\u00f4vodne \u010diasto\u010dne \u00faspe\u0161ne lie\u010den\u00fdch (skupina P) a dokonca nieko\u013eko pacientok z p\u00f4vodne ne\u00faspe\u0161ne lie\u010den\u00fdch (skupina F) bolo tie\u017e bez recid\u00edv alebo maxim\u00e1lne s jednou recid\u00edvou po\u010das dvojro\u010dn\u00e9ho sledovania. Celkov\u00fd podiel pacientok bez recid\u00edv alebo s jednou recid\u00edvou po\u010das 1. roka sledovania bolo 67,21 % a v 2. roku 68,85 %.<\/p>\n

Zistili sme, \u017ee t\u00e1to forma lie\u010dby \u00fa\u010dinne redukuje po\u010det recid\u00edv bakteri\u00e1lnych a mykotick\u00fdch \u00a0kolpit\u00edd. Napriek \u00a0tomu, \u017ee lie\u010dba autovakc\u00ednami je historicky zau\u017e\u00edvan\u00e1 lie\u010debn\u00e1 met\u00f3da chronick\u00fdch \u00a0infekci\u00ed odol\u00e1vaj\u00facich antimikrobi\u00e1lnej lie\u010dbe v okolit\u00fdch \u0161t\u00e1toch, ako s\u00fa \u010cesk\u00e1 republika, Rumunsko, Po\u013esko, n\u00e1\u0161 pr\u00edspevok bol jedin\u00fd, ktor\u00fd sa zaoberal touto problematikou. V odborn\u00fdch \u00a0kruhoch sa v\u0161ak st\u00e1le intenz\u00edvnej\u0161ie zd\u00f4raz\u0148uj\u00fa probl\u00e9my sp\u00f4soben\u00e9 nedostato\u010dnou \u00a0\u00fa\u010dinnos\u0165ou antimikrobi\u00e1lnej terapie a h\u013eadaj\u00fa sa alternat\u00edvne rie\u0161enia. Aj to m\u00f4\u017ee by\u0165 d\u00f4vodom, pre\u010do n\u00e1m dali priestor na takom d\u00f4le\u017eitom podujat\u00ed, a bolo pre n\u00e1s c\u0165ou a pote\u0161en\u00edm prezentova\u0165 na\u0161e v\u00fdsledky aj v zahrani\u010d\u00ed. Poster je dostupn\u00fd na webovej str\u00e1nke: http:\/\/eccmidlive.org\/#resourcegroups\/query=ep0250.<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

V r\u00e1mci predn\u00e1\u0161kov\u00fdch blokov boli vzdel\u00e1vacie workshopy zameran\u00e9 na konkr\u00e9tnu oblas\u0165 alebo aktu\u00e1lnu problematiku, stretnutia s expertmi a r\u00f4zne symp\u00f3zi\u00e1. Bli\u017e\u0161ie inform\u00e1cie o podujat\u00ed n\u00e1jdete na webovej str\u00e1nke http:\/\/www.eccmid.org\/. Po predch\u00e1dzaj\u00facej akt\u00edvnej \u00fa\u010dasti pred dvomi rokmi na 24. ECCMID v Barcelone, \u00a0kde sa n\u00e1m podarilo prv\u00fdkr\u00e1t odprezentova\u0165 \u00a0poster s predbe\u017en\u00fdmi \u00a0v\u00fdsledkami lie\u010dby chronick\u00fdch \u00a0a recidivuj\u00facich<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[292],"tags":[],"class_list":["post-1167","post","type-post","status-publish","format-standard","hentry","category-microbiology","typ_clanku-news"],"acf":{"abstrakt":"

European Congress of Clinical Microbiologists and Infectious Diseases (ECCMID) is the largest annual professional event for physicians, laboratory workers, scientists and researchers in microbiology and infectious diseases. This year\u2019s already 26th<\/sup> ECCMID saw a record-braking attendance \u2013 the event was attended by 11,640 participants from 123 countries all around the world. 4-day program consisted of 113 lectures, 615 electronic posters presented verbally, other 985 electronic posters without verbal presentation and 1 761 paper posters displayed during the congress.<\/p>\n","casopis":[{"ID":991,"post_author":"7","post_date":"2017-02-01 09:43:42","post_date_gmt":"2017-02-01 08:43:42","post_content":"